{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:50Z","timestamp":1786120310246,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822bb573","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T16:04:12Z","timestamp":1317744252000},"page":"653-658","source":"Crossref","is-referenced-by-count":31,"title":["Placebo-Controlled Pilot Study of Ramelteon for Adiposity and Lipids in Patients With Schizophrenia"],"prefix":"10.1097","volume":"31","author":[{"given":"Christina P.C.","family":"Borba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoduo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Freudenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10401230490453293","article-title":"Atypical antipsychotic induced weight gain: pathophysiology and management.","volume":"16","author":"Ananth","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00023210-200216020-00001","article-title":"Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?","volume":"16","author":"Henderson","year":"2002","journal-title":"CNS Drugs"},{"issue":"suppl 6","key":"R3-18-20210128","first-page":"11","article-title":"Schizophrenia and comorbid metabolic disorders.","volume":"66","author":"Henderson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/diabetes.53.8.2087","article-title":"Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome.","volume":"53","author":"Carr","year":"2004","journal-title":"Diabetes"},{"key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/diacare.26.3.650","article-title":"Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans.","volume":"26","author":"Hayashi","year":"2003","journal-title":"Diabetes Care"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI113997","article-title":"Influence of body fat distribution on free fatty acid metabolism in obesity.","volume":"83","author":"Jensen","year":"1989","journal-title":"J Clin Invest"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000119377","article-title":"Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.","volume":"36","author":"Monteleone","year":"1997","journal-title":"Neuropsychobiology"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.npp.1301093","article-title":"Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.","volume":"32","author":"Raskind","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R10-18-20210128","first-page":"181","article-title":"Reduction of night\/day difference in melatonin blood levels as a possible disease-related index in schizophrenia.","volume":"24","author":"Bersani","year":"2003","journal-title":"Neuro Endocrinol Lett"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4088\/JCP.v61n0509","article-title":"Melatonin improves sleep quality of patients with chronic schizophrenia.","volume":"61","author":"Shamir","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00004714-200012000-00017","article-title":"First-night effect of melatonin treatment in patients with chronic schizophrenia.","volume":"20","author":"Shamir","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archpsyc.63.10.1149","article-title":"Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.","volume":"63","author":"Johnson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archpsyc.1992.01820080032005","article-title":"The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description.","volume":"49","author":"Spitzer","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.clinthera.2006.10.016","article-title":"Ramelteon for the treatment of insomnia.","volume":"28","author":"Borja","year":"2006","journal-title":"Clin Ther"},{"key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1079\/BJN19740060","article-title":"Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.","volume":"32","author":"Durnin","year":"1974","journal-title":"Br J Nutr"},{"key":"R17-18-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotics agents. A frequently sampled intravenous glucose tolerance test and Minimal Model analysis.","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psych"},{"key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0969-8043(97)00226-1","article-title":"DXA body composition: theory and practice.","volume":"49","author":"Kelly","year":"1998","journal-title":"Appl Radiat Isot"},{"key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1152\/jappl.1999.87.4.1513","article-title":"Validity of fan-beam dual-energy x-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study-Dual-Energy x-ray Absorptiometry and Body Composition Working Group.","volume":"87","author":"Visser","year":"1999","journal-title":"J Appl Physiol"},{"key":"R20-18-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"R21-18-20210128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2002-20524","article-title":"Simplified measurement of insulin sensitivity with the minimal model procedure in type 2 diabetic patients without measurement of insulinemia.","volume":"34","author":"Perez-Martin","year":"2002","journal-title":"Horm Metab Res"},{"key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s001250051215","article-title":"Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes.","volume":"42","author":"Hermans","year":"1999","journal-title":"Diabetologia"},{"key":"R23-18-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANNS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R24-18-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-18-20210128","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr Bull"},{"key":"R26-18-20210128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","article-title":"Quantification of sleepiness: a new approach.","volume":"10","author":"Hoddes","year":"1973","journal-title":"Psychophysiology"},{"key":"R27-18-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.sleep.2004.07.006","article-title":"Psychometric properties of the Medical Outcomes Study Sleep measure.","volume":"6","author":"Hays","year":"2005","journal-title":"Sleep Med"},{"key":"R28-18-20210128","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials.","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"R29-18-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.plefa.2003.08.010","article-title":"Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment.","volume":"69","author":"Evans","year":"2003","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R30-18-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.smrv.2007.12.005","article-title":"Efficacy and clinical safety of ramelteon: an evidence-based review.","volume":"12","author":"Sateia","year":"2008","journal-title":"Sleep Med Rev"},{"key":"R31-18-20210128","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","article-title":"The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.","volume":"62","author":"Haslemo","year":"2006","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201110000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:43Z","timestamp":1786048063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201110000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822bb573","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}